Ovarian Cancer
Conditions
Keywords
ovarian cancer, long responder
Brief summary
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Interventions
GENETICmolecular analysis
molecular analysis on histological blocks
Sponsors
Centre Jean Perrin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
It is a single-centre study with a prospective part (living patients) and a retrospective part (deceased patients) involving data collection via the patient's medical software. A molecular analysis on histological blocks taken at the time of diagnosis will be carried out as part of the study. This analysis may potentially generate new genomic data to classify patients with ovarian cancer. Could result in the incidental discovery of abnormalities, which may eventually modify the management of the patient, notably her monitoring and screening for other pathologies. No additional sampling will be carried out as part of the study.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment. * Corresponding to one of the two groups below: * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy. * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment * Affiliation to a social security scheme * Patient who signed the genetic consent form
Exclusion criteria
* Minor patient * Pregnant patient * Patient under guardianship or conservatorship * Patients who object to the collection of their medical/paramedical data * Patient for whom the center does not have biological material for genomic analysis (FFPE block) * Patient under administrative, judicial decision or AME (State Medical Aid)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients. | Through study completion, an average of 1 year | Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phenotypic criteria differences between refactory patients and long responder patients | Through study completion, an average of 1 year | Phenotypic criteria will include BMI, personal history and family history |
| Clinical criteria differences between refactory patients and long responder patients | Through study completion, an average of 1 year | Clinical criteria will include age at diagnosis, FIGO stage, initial PCI score, CCO score |
| Biological criteria difference between refactory patients and long responder patients | Through study completion, an average of 1 year | Biological criteria include CA-125 |
| Histological criteria differences between refactory patient and long responder patients | Through study completion, an average of 1 year | Histological criteria include histological type, presence of emboli, Ki-67, RO, RP, WT1, PAX8, PD-L1, CD8, p53, HER2 |
Countries
France
Contacts
CONTACTJudith PASSILDAS JAHANMOHAN, PhD
PRINCIPAL_INVESTIGATORTressie HERRMANN, MD
Centre Jean Perrin
Outcome results
None listed